Long-Term Persistence with Injectable Therapy in Relapsing-Remitting Multiple Sclerosis: An 18-Year Observational Cohort Study-Reference-Cited by-同舟云学术

Long-Term Persistence with Injectable Therapy in Relapsing-Remitting Multiple Sclerosis: An 18-Year Observational Cohort Study

Published:2015-04-13 Issue:4 Volume:10 Page:e0123824
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Zhornitsky Simon,Greenfield Jamie,Koch Marcus W.,Patten Scott B.,Harris Colleen,Wall Winona,Alikhani Katayoun,Burton Jodie,Busche Kevin,Costello Fiona,Davenport Jeptha W.,Jarvis Scott E.,Lavarato Dina,Parpal Helene,Patry David G.,Yeung Michael,Metz Luanne M.

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference38 articles.

1. Progressive multiple sclerosis: pathology and pathogenesis;H Lassmann;Nat Rev Neurol,2012

2. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group;Neurology,1993

3. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group;KP Johnson;Neurology,1995

4. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG);LD Jacobs;Ann Neurol,1996

5. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group;Lancet,1998

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adherence, Persistence, Switching and Costs of Injectable and Oral Therapies for Multiple Sclerosis. Real Life Analysis Over 6 Years of Treatment;Hospital Pharmacy;2024-02-15

2. Real-world persistence to first-line DMTs in relapsing-remitting multiple sclerosis;Multiple Sclerosis and Related Disorders;2023-10

3. Real-world disease-modifying therapy pathways from administrative claims data in patients with multiple sclerosis;BMC Neurology;2022-06-07

4. Effectiveness of first-line treatment for relapsing-remitting multiple sclerosis in Brazil: A 16-year non-concurrent cohort study;PLOS ONE;2020-09-02

5. Persistence, adherence, healthcare resource utilisation and costs for interferon Beta in multiple sclerosis: a population-based study in the Campania region (southern Italy);BMC Health Services Research;2020-08-26